Scripps Research Institute Scientists Reveal Weak Spots in ZMapp's Defense Against Ebola

Updated 8. 13. 15 by StefanCretu

ZMapp, developed by Mapp Biopharmaceutical, was used in August to treat several patients in the ongoing Ebola virus outbreak
Five of the seven patients who received ZMapp survived
Now knowing how ZMapp targets Ebola, scientists can compare all newly discovered anti-Ebola antibodies and formulate a better immunotherapeutic drug

Share This Article

Keep up.

Subscribe to our daily newsletter to keep in touch with the subjects shaping our future.

DISCLAIMER(S)

Articles may contain affiliate links which enable us to share in the revenue of any purchases made.

Registration on or use of this site constitutes acceptance of our Terms of Service.